The effect of SGLT2 inhibitor on diabetic kidney disease-Examination by MRI

The study on the efficacy of SGLT2 inhibitor for DKD using functional MRI - The study on the efficacy of SGLT2 inhibitor for DKD using functional MRI

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000036523

Enrollment

Registered

2019-06-01

Start date

2019-06-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Kidney Disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Both more than eGFR 45 mL/min/1.73m2 and more than ACR 30 mg/g Cr.

Exclusion criteria

Exclusion criteria: # Less than eGFR 45 ml/min/1.73m2 # More than 100 U/L of AST or ALT (excluded patients with fatty liver) # Patients who chenged or increased oral hypoglycemic agents within the past 3 months # Pregnant or breastfeeding women # Patients who have diagnosed with malignancy within the past year # Patients who have had a cardiovascular event or stroke within the past year

Design outcomes

Primary

Measure	Time frame
Changes after 24 weeks in ischemic state of kidney on functional MRI images [T2*value, apparent diffusion coefficient (ADC) value]	—

Countries

Japan

Contacts

Public ContactNobuyuki Koriyama

National Hospital Organization, Kagosima Medical Center The Department of Diabetes and Endocrine Medicine

koriyama.nobuyuki.wm@mail.hosp.go.jp81-099-223-1151

Outcome results